Patent EP0147939A2 successfully refreshed from Google Patents.
EP0147939A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Implantable module for gylcemia regulation
Assignee: Johnson and Johnson
•
Filing: 1984-11-14
•
Granted: —
•
Expires: 2004-11-14
Abstract
Abstract Implantable glycemic regulation module comprising semipermeable membrane encapsulating insulin-producing tissue from the group consisting of human insulinoma cells and human pancreatic islets.
Inventors
- 👤 Jean-Jacques Altman
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 03:15
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0092; A61F; A61F2/00; A61F2/02; A61F2/022; A61K9/0012; A61K9/0019; A61K9/0024; A61L; A61L27/00; A61L27/50; A61L27/54; C; C12; C12N; C12N11/00; C12N11/02; C12N11/04; A61L2300/00; A61L2300/40; A61L2300/43; A61L2300/60; A61L2300/62; A61L2300/64
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
60 words
An implantable module for regulating human glycemia comprising a live insulin-producing source, from the group consisting of a plurality of human insulinoma cells and a plurality of human islets, said source being encapsulated in a hollow fiber membrane material, said membrane material being permeable to insulin and other endocrine hormones, cell waste products, and cell nutrients, and impermeable to immunocytes.
Claim 2
Dependent Claim
60 words
An implantable module for regulating human glycemia comprising a live insulin-producing source, from the group consisting of a plurality of human insulinoma cells and a plurality of human islets, said source being encapsulated in a hollow fiber membrane material, said membrane material being permeable to insulin and other endocrine hormones, cell waste products, and cell nutrients, and impermeable to immunocytes.
Claim 3
Dependent Claim
14 words
The module of claim 1, wherein said insulin source comprises live human insulinoma cells.
Claim 4
Dependent Claim
13 words
The module of claim 1, wherein said insulin source comprises human pancreatic islets.
Claim 5
Dependent Claim
16 words
The module of any one of claims 1 to 3 for use in regulating human glycemia.
Claim 6
Independent Claim
65 words
A method of producing a module according to any one of claims 1 to 3, comprising encapsulating a live insulin-producing source, from the group consisting of a plurality of human insulinoma cells and a plurality of human islets, in a hollow fiber membrane material, said membrane material being permeable to insulin and other endocrine hormones, cell waste products, and cell nutrients, and impermeable to immunocytes.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.